This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Icagen Reports Fourth Quarter And Full Year 2010 Financial Results And Operational Highlights

RESEARCH TRIANGLE PARK, N.C., March 7, 2011 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) reported today its financial results and operational highlights for the fourth quarter and full year ended December 31, 2010. For the fourth quarter of 2010, the Company reported revenues of $2.3 million and a net loss of $724,000. For the full year 2010, the Company reported revenues of $10.5 million and a net loss of $6.4 million. As of December 31, 2010, the Company's cash and cash equivalents totaled $12.0 million. 

"We are pleased that clinical development of a selective Nav1.7 (SCN9A) compound has been initiated in our collaboration with Pfizer.  While there are several currently marketed sodium channel blockers, none are selective for this particular target, which has been genetically linked to various pain disorders.  We therefore believe that targeting Nav1.7 with this novel compound may represent a unique and promising approach to the treatment of certain pain conditions.  We look forward to continued progress in this program, in which we, together with Pfizer, have identified multiple promising compounds," noted P. Kay Wagoner, CEO of Icagen.  "We are also pleased to be in a position to continue the development of ICA-105665, our novel KCNQ agonist for the treatment of epilepsy and pain, following discussions with the FDA."

Pipeline Update

Pfizer Collaboration: During the second half of 2010, the Company announced the initiation of a Phase I clinical trial with a candidate compound in the Nav1.7 (SCN9A) program for the treatment of pain, as well as the extension of the research term of the collaboration through December 2011. In addition, the Company received $4.0 million of milestone payments from Pfizer resulting from progress made in the collaboration, which continues to focus on the identification of novel compounds targeting three specific sodium channels for the treatment of pain.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.73 -1.20%
FB $117.61 0.75%
GOOG $692.53 0.22%
TSLA $240.58 -2.90%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,066.17 -9.64 -0.46%
NASDAQ 4,776.3210 -28.97 -0.60%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs